Global Exclusivity Divergence: Hatch-Waxman PTE Versus European SPC Extensions
1. The Economics of Time in Biopharma Biopharmaceutical asset valuation rests on a single, volatile variable: the duration of market […]
Global Exclusivity Divergence: Hatch-Waxman PTE Versus European SPC Extensions Read Post »









